KDR and adrenal cortex carcinoma: Dovitinib, axitinib, sunitinib, regorafenib, sorafenib, nintedanib, and lenvatinib are drugs mainly targeting VEGFR and PDGFR, and they have been tested in phase II clinical trials enrolling patients with advanced chemo-refractory ACC (Table 1).